Summary of Product Characteristics
last updated on the eMC:
09/07/2010
When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.
Updated on 09/07/2010 and displayed until Current
|
Reasons for adding or updating:
|
-
Change to section 4.2 - Posology and method of administration
|
| Date of revision of text on the SPC: 06-Jul-2010 |
| Legal Category: POM |
| Black Triangle (CHM):
NO |
Free-text change information supplied by the pharmaceutical company
|
| Following internal review this section has been updated to improve clarity of presentation and to bring it in line with (and ensure consistency with) current recommendations for best practice including the British Thoracic Society Guideline on the Management of Asthma [The new 2008 guideline (revised June 2009)] and standard reference texts.
|
|
Updated on 10/12/2008 and displayed until 09/07/2010
|
Reasons for adding or updating:
|
-
Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
-
Change to section 4.2 - Posology and method of administration
|
| Date of revision of text on the SPC: 30-Oct-2008 |
| Legal Category: POM |
| Black Triangle (CHM):
NO |
Free-text change information supplied by the pharmaceutical company
|
| Sections updated to correct typographical errors
|
|
Updated on 30/06/2008 and displayed until 10/12/2008
|
Reasons for adding or updating:
|
-
New SPC for eMC ie an SPC for an existing product, but one that is new for the eMC
|
| Date of revision of text on the SPC: |
| Legal Category: POM |
| Black Triangle (CHM):
NO |
Free-text change information supplied by the pharmaceutical company
|
| None provided |
|